.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Pediatric high-grade central nervous system neoplasms represent the leading cause of cancer-related death in children. Standard therapies such as neurosurgical resection, craniospinal irradiation, and cytotoxic chemotherapy frequently fail to achieve durable remission. Consequently, oncologists are intensely exploring cellular immunotherapies, particularly chimeric antigen receptor T-cell strategies. The immune checkpoint glycoprotein B7-H3, encoded by CD276, represents an attractive target due to reported expression across pediatric malignancies. However, clinicians debate whether baseline B7-H3 immunohistochemistry is strictly necessary before enrolling patients in clinical trials. Early trials often assumed universal antigen expression, enrolling children without prospective tissue re-biopsy or target confirmation. Nevertheless, emerging evidence demonstrates substantial expression heterogeneity within pediatric brain tumors. If significant tumor subsets lack adequate target density, unselected trial inclusion exposes children to toxicities without therapeutic benefit. Therefore, determining the exact biomarker role of tissue immunohistochemistry has become an urgent clinical priority.
To resolve this crucial translational question, researchers at the Princess Máxima Center conducted a comprehensive retrospective study. Investigators analyzed 136 pediatric high-grade central nervous system tumor specimens with matched clinicopathological records. Specifically, this expansive cohort included 58 high-grade gliomas, 44 embryonal tumors, 30 ependymomas, and 4 high-grade neuroepithelial neoplasms. The research team evaluated CD276 messenger RNA abundance alongside quantitative B7-H3 protein expression using standardized immunohistochemical protocols. Furthermore, they correlated these staining results with detailed clinical, anatomical, and epigenetic profiling data. The experimental findings revealed striking variability in both transcription and surface protein expression across all evaluated tumor types. Although numerous tumors showed robust immunoreactivity, the distribution of antigen density varied dramatically. Importantly, rigorous pathological quality assessments confirmed that negative staining reflected genuine biological absence rather than technical artifact. Because all analyzed specimens demonstrated high tumor cellularity, inadequate sampling did not explain negative findings. Thus, this study confirms that B7-H3 is not universally expressed in pediatric neuro-oncology.
The study revealed striking heterogeneity across distinct molecular and histopathological entities. Most notably, approximately 30 percent of diffuse midline gliomas with H3K27 alterations displayed minimal or absent protein expression. Similarly, nearly one-third of posterior fossa type A ependymomas exhibited no detectable target antigen. This finding surprised clinicians who previously regarded these lethal subtypes as ideal candidates for uniform B7-H3 targeting. Furthermore, statistical evaluations proved that this erratic expression pattern did not correlate with patient age, tumor location, or epigenetic subclass. Molecular drivers and underlying oncogenic alterations also failed to predict which neoplasms retained target expression. In several specimens, positive staining localized exclusively to vascular endothelial cells rather than neoplastic parenchyma. While endothelial staining may produce weak positive scores, CAR-T activation requires extensive target density directly on malignant cells. Consequently, physicians cannot reliably predict antigen presence using standard molecular or radiographic surrogates alone. Instead, direct immunohistochemical assessment provides the only definitive confirmation of target availability.
These biological insights carry critical ramifications for designing future pediatric neuro-oncology clinical trials. Contemporary adoptive cellular therapies require robust immunological synapse formation between engineered CAR-T cells and target surface proteins. When antigen density falls below a critical threshold, infused lymphocytes fail to trigger cytotoxic degranulation. Under these suboptimal conditions, engineered cells undergo rapid functional exhaustion or premature clearance without providing tumor control. Consequently, enrolling children with antigen-negative tumors compromises patient safety while obscuring true therapeutic efficacy in clinical trials. In addition, patients frequently undergo neurosurgical procedures, such as Ommaya reservoir placement, for repeated intracerebroventricular cell infusions. Exposing vulnerable children to surgical risks without confirmed target expression presents serious ethical concerns. Therefore, trial steering committees must mandate tissue acquisition and biomarker validation at enrollment. By establishing clear target expression criteria, investigational protocols can optimize candidate selection, prevent unnecessary procedural risks, and preserve experimental integrity. Ultimately, rigorous patient stratification ensures that cellular immunotherapies reach patients most likely to benefit.
Establishing uniform diagnostic standards across international centers remains an urgent objective for translational neuro-oncology. Historically, laboratory teams utilized varying scoring methodologies, ranging from simple binary positivity to composite histological scores, or H-scores. The H-score combines both the percentage of stained neoplastic cells and relative staining intensity across the sample. For example, recent phase 1 cellular therapy protocols require an H-score exceeding 100 for patient eligibility. However, global standardization remains difficult because pathology laboratories utilize differing primary antibody clones, retrieval techniques, and automated platforms. Furthermore, pathologists must carefully distinguish true tumor membrane staining from background stromal reactivity or isolated vascular signals. To resolve these challenges, international consortia must develop harmonized staining protocols and reproducible digital pathology scoring criteria. Implementing centralized pathology review will substantially reduce inter-observer discordance across multicenter studies. In addition, assessing repeat biopsies at recurrence is vital, as prior therapies can induce antigen loss. Therefore, standardized longitudinal biomarker tracking must become standard practice in neuro-oncology trials.
These research findings offer vital guidance for pediatric oncologists and neurosurgeons practicing across India. Tertiary oncology centers in India frequently care for children presenting with refractory midline gliomas, medulloblastomas, and high-grade gliomas. Moreover, academic institutions and domestic biotechnology companies are actively manufacturing indigenous CAR-T cellular products. As these innovative trial protocols expand nationwide, adopting evidence-based biomarker inclusion criteria is essential. Enrolling pediatric patients without confirmed target expression imposes severe clinical and financial burdens on families funding advanced care. Additionally, neurosurgical teams must carefully balance the risks of surgical re-biopsy against the clinical futility of unguided experimental therapy. Therefore, Indian neuropathology laboratories should actively validate reliable CD276 immunohistochemistry assays on automated diagnostic systems. Multidisciplinary tumor boards must scrutinize antigen status and tissue availability before recommending cellular therapy trials or novel targeted infusions. Ultimately, adopting mandatory biomarker screening will optimize healthcare resources, ensure equitable trial access, and improve clinical outcomes for Indian children facing malignant central nervous system neoplasms.
B7-H3, also known as CD276, is an immune checkpoint glycoprotein frequently overexpressed across diverse pediatric solid tumors and central nervous system malignancies. Because normal human brain tissues exhibit minimal baseline expression, B7-H3 represents an exceptionally attractive target for antigen-directed immunotherapies, such as chimeric antigen receptor T cells and antibody-drug conjugates.
No, clinical and molecular characteristics cannot reliably substitute for direct protein testing. Comprehensive analyses confirm that target expression varies independently of patient age, tumor location, epigenetic subgroup, and underlying driver mutations. Consequently, direct immunohistochemical quantification on tumor tissue remains the only dependable method to confirm adequate antigen presence before initiating targeted cellular therapies.
Omitting baseline biomarker testing risks enrolling children whose tumors lack the target antigen entirely. Consequently, these patients receive ineffective, highly intensive experimental treatments and face surgical complications from delivery catheters without clinical benefit. Furthermore, including antigen-negative subjects dilutes trial efficacy metrics, potentially derailing promising cellular therapy programs during clinical development.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Evaluating B7-H3 expression via immunohistochemistry is crucial for pediatric high-grade CNS tumor clinical trials. A study shows 30% of diffuse midline gliomas and ependymomas lack expression, underscoring the need for mandatory tissue testing to optimize CAR-T patient selection.
Today
A feasibility study evaluates remote vital sign monitoring in acute hospital at home patients. Continuous wearable patches captured heart rate and respiratory rate with high adherence (89% and 75%), significantly exceeding manual spot checks for blood pressure, oxygen saturation, and temperature.
Today
A scoping review evaluates 116 studies on AI in women's reproductive health, finding that 83.6% carry high risk of bias. While ensemble models show promise, disparities and lack of validation hinder LMIC deployment.
Today
Differential oxygenation during peripheral TA-NRP can cause undetected coronary hypoxemia due to arch vessel clamping. A novel circuit with continuous aortic root monitoring detects desaturation early, facilitating left ventricular unloading and preventing allograft dysfunction and unnecessary heart discard.
Today
A longitudinal study reveals that patients undergoing staged bilateral hip arthroscopy experience progressive contralateral labral deterioration during surgical intervals. However, structural degradation does not compromise 2-year postoperative clinical outcomes or patient-reported satisfaction scores.
Today
A post hoc analysis of the PARM-T2D study shows pemafibrate exerts baseline-dependent effects on LDL-C and particle size in type 2 diabetes and hypertriglyceridemia. It lowers triglycerides and remnants while favorably remodeling atherogenic LDL particles based on initial lipid control status.
Today
